These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37850940)

  • 1. A Staphylococcus capitis strain with unusual bacteriocin production.
    Szekat C; Josten M; Rickmeyer J; Crüsemann M; Bierbaum G
    Microb Biotechnol; 2023 Nov; 16(11):2181-2193. PubMed ID: 37850940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of vancomycin-intermediate and -resistant Staphylococcus aureus among methicillin-resistant S. aureus isolated from clinical specimens in the northwest of Iran.
    Ghahremani M; Jazani NH; Sharifi Y
    J Glob Antimicrob Resist; 2018 Sep; 14():4-9. PubMed ID: 29454049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of the Bsa lantibiotic by community-acquired Staphylococcus aureus strains.
    Daly KM; Upton M; Sandiford SK; Draper LA; Wescombe PA; Jack RW; O'Connor PM; Rossney A; Götz F; Hill C; Cotter PD; Ross RP; Tagg JR
    J Bacteriol; 2010 Feb; 192(4):1131-42. PubMed ID: 20023032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lantibiotic gallidermin acts bactericidal against Staphylococcus epidermidis and Staphylococcus aureus and antagonizes the bacteria-induced proinflammatory responses in dermal fibroblasts.
    Bengtsson T; Lönn J; Khalaf H; Palm E
    Microbiologyopen; 2018 Dec; 7(6):e00606. PubMed ID: 29536668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nisin J, a Novel Natural Nisin Variant, Is Produced by Staphylococcus capitis Sourced from the Human Skin Microbiota.
    O'Sullivan JN; O'Connor PM; Rea MC; O'Sullivan O; Walsh CJ; Healy B; Mathur H; Field D; Hill C; Ross RP
    J Bacteriol; 2020 Jan; 202(3):. PubMed ID: 31740495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervimycin-Resistant Staphylococcus aureus Strains Display Vancomycin-Intermediate Resistant Phenotypes.
    Dietrich A; Steffens U; Gajdiss M; Boschert AL; Dröge JK; Szekat C; Sass P; Malik IT; Bornikoel J; Reinke L; Maček B; Franz-Wachtel M; Nieselt K; Harbig T; Scherlach K; Brötz-Oesterhelt H; Hertweck C; Sahl HG; Bierbaum G
    Microbiol Spectr; 2022 Oct; 10(5):e0256722. PubMed ID: 36173303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The two-component regulatory systems GraRS and SrrAB mediate
    Suzuki Y; Kawada-Matsuo M; Le MN-T; Eng S; Hisatsune J; Sugai M; Sakaguchi T; Komatsuzawa H
    Appl Environ Microbiol; 2024 Jul; 90(7):e0030024. PubMed ID: 38832774
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of an Amplicon Nanopore Sequencing Strategy for Detection of Mutations Conferring Intermediate Resistance to Vancomycin in Staphylococcus aureus Strains.
    Moller AG; Petit RA; Davis MH; Read TD
    Microbiol Spectr; 2023 Feb; 11(1):e0272822. PubMed ID: 36688645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Draft genome sequence of Staphylococcus agnetis 3682, the producing strain of the broad-spectrum lantibiotic agneticin 3682.
    Fagundes PC; Francisco MS; Sousa Santos IN; Marques-Bastos SLS; Paz JAS; Albano RM; do Carmo de Freire Bastos M
    J Glob Antimicrob Resist; 2019 Dec; 19():50-52. PubMed ID: 31454564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Characterization of Methicillin and Vancomycin Resistant
    Jahanshahi A; Zeighami H; Haghi F
    Microb Drug Resist; 2018 Dec; 24(10):1529-1536. PubMed ID: 29883257
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanisms of vancomycin resistance in Staphylococcus aureus.
    Gardete S; Tomasz A
    J Clin Invest; 2014 Jul; 124(7):2836-40. PubMed ID: 24983424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin Resistance in
    McGuinness WA; Malachowa N; DeLeo FR
    Yale J Biol Med; 2017 Jun; 90(2):269-281. PubMed ID: 28656013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections.
    Sivori F; Cavallo I; Kovacs D; Guembe M; Sperduti I; Truglio M; Pasqua M; Prignano G; Mastrofrancesco A; Toma L; Pimpinelli F; Morrone A; Ensoli F; Di Domenico EG
    Microbiol Spectr; 2022 Apr; 10(2):e0035122. PubMed ID: 35416701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sub-Inhibitory Concentrations of Oxacillin, but Not Clindamycin, Linezolid, or Tigecycline, Decrease Staphylococcal Phenol-Soluble Modulin Expression in Community-Acquired Methicillin-Resistant Staphylococcus aureus.
    Hodille E; Beraud L; Périan S; Berti V; Bes M; Tristan A; Blond E; Lina G; Dumitrescu O
    Microbiol Spectr; 2022 Feb; 10(1):e0080821. PubMed ID: 35044221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a Novel Gene Associated with High-Level β-Lactam Resistance in Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Strain Mu3 and Methicillin-Resistant S. aureus Strain N315.
    Matsuo M; Yamamoto N; Hishinuma T; Hiramatsu K
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
    Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp.
    Yoneda A; Thänert R; Burnham CD; Dantas G
    Int J Antimicrob Agents; 2020 Feb; 55(2):105864. PubMed ID: 31870598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterisation of capidermicin, a novel bacteriocin produced by Staphylococcus capitis.
    Lynch D; O'Connor PM; Cotter PD; Hill C; Field D; Begley M
    PLoS One; 2019; 14(10):e0223541. PubMed ID: 31618225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methicillin-resistant and vancomycin-intermediate Staphylococcus aureus colonizing patients and intensive care unit environment: virulence profile and genetic variability.
    Veloso JO; Lamaro-Cardoso J; Neves LS; Borges LFA; Pires CH; Lamaro L; Guerreiro TC; Ferreira EMA; André MCP
    APMIS; 2019 Nov; 127(11):717-726. PubMed ID: 31407405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.